Book chapter
Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways
Cystic Fibrosis in the Light of New Research
IntechOpen
08/24/2015
DOI: 10.5772/60977
Abstract
An important goal for cystic fibrosis (CF) gene therapy is to achieve long-term functional correction. While many vector options have been evaluated, integrating vectors have the greatest potential to maintain stable expression over time without a requirement for repeated administration. In this chapter, we discuss the importance of correcting the appropriate cell types, options for integrating vectors, animal models for CF gene therapy, and clinically relevant endpoint measurements. Lentiviral vectors are a promising option for CF gene therapy, as they integrate into the host genome and persistently express a transgene of interest. Airway cell tropism can be conferred by pseudotyping. Nonviral vectors such as DNA transposons can also integrate into the genome. Recent advances in hybrid viral/transposon vector technology improve the ability to deliver transposons to the airways in vivo. Integrating vector technology and new animal models have allowed considerable progress toward the goal of using gene therapy to correct life-long genetic diseases such as CF.
Details
- Title: Subtitle
- Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways
- Creators
- Ashley L Cooney - University of IowaPaul B McCray Jr - University of Iowa, Pulmonary MedicinePatrick L Sinn - University of Iowa, Pulmonary Medicine
- Contributors
- Dennis Wat (Editor)
- Resource Type
- Book chapter
- Publication Details
- Cystic Fibrosis in the Light of New Research
- Publisher
- IntechOpen
- DOI
- 10.5772/60977
- Language
- English
- Date published
- 08/24/2015
- Academic Unit
- Microbiology and Immunology; Internal Medicine; Stead Family Department of Pediatrics; Pulmonary Medicine
- Record Identifier
- 9984746167102771
Metrics
2 Record Views